Clinical Utility of the Cryptococcal Antigen Lateral Flow Assay in a Diagnostic Mycology Laboratory

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  McMullan, Brendan J ^a,b   Halliday, Catriona ^a   Sorrell, Tania C ^c,d   Judd, David ^a   Sleiman, Sue ^a   Marriott, Debbie ^e   Olma, Tom ^a   Chen, Sharon C A ^a,c,d  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTOCOCCAL ANTIGEN; FUNGUS ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; COST BENEFIT ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LATERAL FLOW IMMUNOASSAY; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; MYCOLOGY; NONHUMAN; POINT OF CARE TESTING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; HUMANS; IMMUNOLOGIC TESTS; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

FILOBASIDIELLA NEOFORMANS;

EID: 84869137861     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049541     Document Type: Article

References (23)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
2. Pukkila-Worley R, Mylonakis E, (2008) Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother 9: 551-560.
3. Chau TT, Mai NH, Phu NH, Nghia HD, Chuong LV, et al. (2010) A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam- high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis 10: 199.
4. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, et al. (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499-508.
5. Speed B, Dunt D, (1995) Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21: 28-34 discussion 35-26.
6. Jenney A, Pandithage K, Fisher DA, Currie BJ, (2004) Cryptococcus infection in tropical Australia. J Clin Microbiol 42: 3865-3868.
7. Galanis E, Macdougall L, (2010) Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 16: 251-257.
8. Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, et al. (2011) Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 53: 1188-1195.
9. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, et al. (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20: 2183-2191.
10. Shea Y (2011) General Approaches for Direct Detection of Fungi. In: Manual of clinical microbiology. Versalovic J editor. 10th ed. Washington, DC: ASM Press. p. 1783.
11. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
12. IMMY Cryptococcal Antigen Lateral Flow Assay. Available: http://www.immy.com/products/cryptococcal-antigen-lateral-flow-assay-lfa/. Accessed: 29 July 2012.
13. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53: 321-325.
14. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019-1023.
15. Rajasingham R, Meya DB, Boulware DR, (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
16. Meridien Bioscience, Inc. Cryptococcal Antigen Latex Agglutination System (CALAS®). Available: http://www.meridianbioscience.com/diagnostic-products/cryptococcal-antigen-and-coccidiodes/latex-agglutination/cryptococcal-antigen-latex-agglutination-system-calas.aspx. Accessed: 29 July 2012.
17. Howell S, Hazen K (2011) Candida, Cryptococcus and Other Yeasts. In: Manual of clinical microbiology. Versalovic J editor. 10th ed. Washington, DC: ASM Press. pp. 1803-1810.
18. Snyder J, Atlas R, Larocco M (2011) Reagents, Stains and Media: Mycology. In: Manual of Clinical Microbiology. Versalovic J editor. 10th ed. Washington DC: ASM Press. p. 1771.
19. Lau A, Chen S, Sorrell T, Carter D, Malik R, et al. (2007) Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 45: 380-385.
20. Brown LC, T, (2001) DasGupta A, (2001) Interval Estimation for a Binomial Proportion. Statistical Science 16: 101-133.
21. Bland JM, Altman DG, (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310.
22. WHO, editor (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva, Switzerland: WHO press.
23. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4: e21.